Tobacco use among youth and young adults is a large health concern. NCHR wrote a comment to the CDC regarding efforts to minimize usage among this population.
Read More »On Health Policy
The USPSTF Draft Recommendations on Medication Use to Prevent Breast Cancer: Comments by Women’s Health Experts
NCHR writes on behalf of five nonprofit health organizations that have examined issues pertaining to primary prevention of breast cancer for decades and urge the USPSTF to consider revising their current recommendations on breast cancer risk reducing drugs.
Read More »NCHR comments on FDA’s Framework for Real-World Evidence Program
February 5, 2019. FDA needs to maintain high standards for evidence of effectiveness and safety whether the source of the data is from traditional clinical trials or RWE. Double-blind, randomized clinical trials remain the gold standard, and along with other types of well-controlled trials (including those that generate RWE), provide information that observational studies cannot. RWE should supplement rather than replace traditional, randomized and blinded controlled clinical trials except in situations where such traditional clinical trials are not possible.
Read More »NCHR Comments on USPSTF Draft Recommendation Statement on Hepatitis B Virus Screening in Pregnant Women
February 4, 2019. We support USPSTF’s draft recommendation on hepatitis B virus infection screening in pregnant women.
Read More »NCHR Comments on USPSTF’s Draft Research Plan for Colorectal Cancer: Screening
January 30, 2019. We strongly support the USPSTF’s efforts to update recommendations for different types of colorectal cancer screening for different demographic subgroups, as well as their broader efforts to improve the health of all Americans by making evidence-based recommendations about clinical preventive services.
Read More »